Wegovy for Cardiovascular Prevention: What Insurance Actually Covers and What You Will Really Pay

The Short Answer: Is Wegovy Approved for Heart Disease Prevention?

Yes, but with a specific label. In March 2024, the FDA approved an expanded indication for Wegovy to reduce the risk of serious cardiovascular events, defined as non-fatal heart attack, non-fatal stroke, and cardiovascular death, in adults who have established cardiovascular disease and a body mass index of 27 or above. This approval was based on the SELECT trial, a landmark study published in the New England Journal of Medicine in November 2023.

That matters for women, and here is why. Cardiovascular disease is the leading cause of death in American women, accounting for approximately one in three female deaths each year, according to the American Heart Association. Yet women are routinely under-diagnosed, under-treated, and under-represented in cardiovascular trials. The SELECT trial enrolled 17,604 participants but only about 24% were women, a proportion the trial investigators themselves noted as a limitation.

What "Established CVD" Means for Women

The SELECT trial required participants to have a prior heart attack, prior stroke, or symptomatic peripheral arterial disease. Women presenting for Wegovy coverage under the cardiovascular indication need documented evidence of one of those three conditions. A family history of heart disease, elevated coronary calcium score, or high 10-year ASCVD risk alone will not meet the FDA label criteria. Those uses remain off-label.

The Off-Label Gray Zone

Clinicians may still prescribe Wegovy for primary cardiovascular prevention, meaning preventing a first event in high-risk women who do not yet have established disease. That use is off-label. Prescribing off-label is legal and common, but it almost certainly will not be covered by insurance under the cardiovascular justification. We will return to this in the coverage section.

What the SELECT Trial Actually Found for Women

The SELECT trial showed a 20% relative risk reduction in major adverse cardiovascular events (MACE) compared to placebo over a median follow-up of 34.2 months, in people who had obesity or overweight and pre-existing cardiovascular disease but no diabetes. The absolute risk reduction was 1.5 percentage points (6.5% vs. 8.0%).

Sex-Stratified Results: What We Know and What We Do Not

The pre-specified subgroup analysis by sex showed a hazard ratio of 0.76 (95% CI 0.65 to 0.90) in men and 0.84 (95% CI 0.62 to 1.13) in women for the primary MACE endpoint. The confidence interval in women crossed 1.0, meaning the female-specific result was not statistically significant on its own. This is a direct consequence of the low female enrollment. The point estimates trended in the same direction, but the trial was not powered to confirm efficacy in women independently.

This is an evidence gap you deserve to know about. The benefit seen in SELECT is extrapolated to women rather than confirmed in women at the same statistical confidence level as in men. Your clinician should discuss this distinction with you, particularly if you are considering Wegovy specifically for cardiovascular prevention rather than weight management.

Perimenopause, Post-Menopause, and Cardiovascular Risk

Estrogen's withdrawal at menopause accelerates several cardiovascular risk factors: LDL cholesterol rises, HDL cholesterol falls, visceral fat increases, blood pressure tends to climb, and insulin resistance worsens. The Nurses' Health Study and subsequent analyses established that the rate of coronary heart disease in women roughly doubles in the decade following menopause. Wegovy's effects on body weight, blood pressure (SELECT showed a mean reduction of approximately 3 mmHg systolic), and lipids are mechanistically relevant to post-menopausal cardiovascular risk. But SELECT enrolled women across all ages and did not publish a menopause-stratified subgroup. The benefit in post-menopausal women specifically remains an open research question.

Insurance Coverage: The Real Picture in 2025

"FDA-approved for cardiovascular prevention" and "covered by your insurance for that reason" are two entirely different things. Here is how each payer category breaks down.

Commercial (Employer-Sponsored) Insurance

Coverage is inconsistent and plan-dependent. Some large employers added GLP-1 coverage for obesity in 2023 and 2024, but a 2024 KFF Employer Health Benefits Survey found that only about 25% of large employers covered GLP-1 drugs for weight loss. The cardiovascular indication does not automatically trigger coverage; your plan's formulary must list the drug and your plan's medical policy must accept the cardiovascular diagnosis code.

What to do: Ask your HR benefits team specifically whether Wegovy is on formulary for the ICD-10 codes Z86.73 (personal history of transient ischemic attack) or I25.10 (atherosclerotic heart disease). Prior authorization is almost universal, requiring documentation of your BMI, your cardiovascular diagnosis, and evidence that you have tried lifestyle modification.

Medicare Part D

This is where the SELECT trial data produced a concrete policy change. CMS announced in April 2024 that Medicare Part D plans can cover semaglutide 2.4 mg for the cardiovascular indication in qualifying beneficiaries. This is a significant shift because Medicare had historically excluded weight-loss drugs from Part D coverage.

The catch: "can cover" does not mean "must cover." Individual Part D plans still decide whether to include Wegovy on their formulary. As of early 2025, formulary inclusion varies by plan. If you are on Medicare, you need to check your specific Part D plan's 2025 formulary, not just the CMS announcement.

For women in their mid-60s and beyond who have had a prior heart attack or stroke, this coverage pathway is potentially the most accessible, but it requires persistence and often an appeal.

Medicaid

Medicaid coverage of GLP-1 drugs varies by state. Some states cover them under the obesity benefit; others exclude them entirely. The cardiovascular indication does not uniformly override state exclusions. Check your state's Medicaid drug formulary directly.

Prior Authorization: What Triggers a Denial and How to Fight It

The most common reasons for prior authorization denial include:

• BMI documented below the threshold (you need BMI of 27 or above for the CV indication, 30 or above for the obesity-only indication)
• Missing documentation of established CVD (the chart note must name MI, stroke, or PAD explicitly)
• No documented trial of lifestyle intervention
• Step therapy requirements (some plans require metformin or a different GLP-1 first)

An appeal with a detailed letter of medical necessity from your cardiologist or OB-GYN citing the SELECT trial and the 2024 FDA label change has a reasonable chance of success, particularly on second-level appeals. The American Heart Association's 2023 statement on obesity pharmacotherapy can be attached as supporting literature.

What You Will Actually Pay Out of Pocket

The list price for Wegovy in the United States is approximately $1,349 per month as of 2024, per Novo Nordisk's published wholesale acquisition cost. Few patients pay that amount, but what you pay depends on your coverage situation.

With Commercial Insurance Coverage

Novo Nordisk offers a savings card program that can reduce your copay to as low as $25 per month if you have commercial insurance. Eligibility is limited: you must have a commercial plan that covers Wegovy, you cannot be on Medicare or Medicaid, and the plan cannot be a high-deductible plan that hasn't met its deductible yet. Savings cards do not apply to government insurance.

Without Coverage

Without insurance, you are looking at the full list price or a compounding pharmacy alternative. Compounded semaglutide (not Wegovy, not FDA-approved) became widely available during the 2023 to 2024 shortage period. The FDA removed semaglutide from the shortage list in February 2025, which means compounding pharmacies that were operating under shortage exemptions must wind down compounded semaglutide. If you are currently using compounded semaglutide for cardiovascular prevention, discuss a transition plan with your prescriber.

GoodRx and Mark Cuban's Cost Plus Drugs

Neither GoodRx nor Cost Plus Drugs carries Wegovy at a meaningfully reduced price because semaglutide has no generic equivalent. GoodRx prices for Wegovy run between $1,200 and $1,350 per month depending on pharmacy. This is unlikely to change before semaglutide's core patents expire, which is not expected before the early 2030s.

Who This Indication Is Right For, and Who Should Pause

Women Who May Qualify for Covered Wegovy Under the CV Indication

• Post-menopausal women with a documented prior MI, stroke, or PAD and BMI of 27 or above
• Perimenopausal women who experienced a cardiovascular event and whose weight management has been difficult due to hormonal changes affecting appetite and fat distribution
• Women with obesity and established CVD who have tried lifestyle modification and whose cardiologist supports pharmacotherapy

Women for Whom the CV Indication Does Not Apply (and What to Do Instead)

• Women with high ASCVD risk but no prior event: the cardiovascular indication does not apply. You may still qualify for Wegovy under the obesity indication (BMI of 30 or above, or BMI of 27 or above with a weight-related comorbidity like hypertension, sleep apnea, or dyslipidemia). Insurance coverage through the obesity pathway has different, sometimes more accessible, criteria depending on your plan.

• Women with PCOS and elevated cardiovascular risk: PCOS raises the lifetime cardiovascular risk substantially. A 2023 meta-analysis in Fertility and Sterility confirmed that PCOS is associated with a 1.5 to 2-fold increased risk of incident cardiovascular disease. Wegovy has shown benefit in insulin resistance and weight in PCOS (through the obesity indication), but the CV indication requires prior established disease, not elevated risk alone.

• Women currently trying to conceive or pregnant: Wegovy is contraindicated. See the section below.

• Women with a personal or family history of medullary thyroid cancer or MEN2: Wegovy carries a black-box warning and is contraindicated in these groups regardless of cardiovascular status.

Pregnancy, Lactation, and Contraception: Non-Negotiable Facts

Wegovy is contraindicated during pregnancy. This is not a precaution. It is a hard contraindication based on animal reproductive studies showing fetal harm at clinically relevant exposures, per the FDA prescribing information.

If You Are of Reproductive Age

Novo Nordisk and the FDA recommend stopping Wegovy at least two months before attempting to conceive. Semaglutide has a long half-life of approximately one week, meaning it takes multiple weeks to clear your system even after the last dose.

If you become pregnant while on Wegovy, stop the drug immediately and contact your clinician. The Novo Nordisk pregnancy exposure registry is collecting outcomes data, but human safety data in pregnancy remains very limited. Animal studies showed structural fetal abnormalities at doses below the clinical human dose.

Contraception Requirement

Oral contraceptives may have reduced absorption during the early weeks of semaglutide treatment due to delayed gastric emptying. The SELECT trial protocol and the prescribing label recommend using a barrier method or switching to a non-oral contraceptive for four weeks after starting and for four weeks after each dose increase.

If you are in perimenopause and not yet confirmed post-menopausal (defined as 12 consecutive months without a period), you still need contraception while on Wegovy.

Lactation

There are no human data on semaglutide transfer into breast milk. Animal studies show transfer occurs. Given the absence of safety data and the theoretical risk to the infant, the FDA prescribing information advises against use during breastfeeding. Discuss the risks and your individual circumstances with your prescriber before making a decision.

Sex-Specific Side Effects and What to Watch For

Women in clinical trials of semaglutide have reported higher rates of nausea and vomiting than men, consistent with known sex differences in gastric motility. A pooled analysis of STEP trials showed that gastrointestinal adverse events led to discontinuation in approximately 4.5% of women versus 2.8% of men, though this comparison was not pre-specified and should be interpreted with caution.

Muscle mass preservation is a specific concern for women starting Wegovy for cardiovascular or weight indications. Women have lower baseline muscle mass than men and are more vulnerable to sarcopenia with rapid weight loss. The American College of Obstetricians and Gynecologists recommends that women on GLP-1 therapy prioritize resistance training and adequate protein intake (at least 1.2 g per kg body weight per day) to preserve lean mass, per ACOG's 2023 obesity management guidance.

Bone density is a secondary concern, particularly in post-menopausal women. Rapid weight loss from any cause can reduce bone mineral density. If you are already on treatment for osteoporosis or have a T-score below minus 2.0, discuss monitoring frequency with your clinician before starting Wegovy.

Practical Steps to Pursue Coverage

1. Get your cardiologist or primary care physician to document the specific CVD event (MI, stroke, or PAD) and current BMI in the chart note using explicit language.
2. Request that the prior authorization submission reference CPT code J3490 or J3590 (for injections) and the FDA's March 2024 cardiovascular indication approval.
3. Attach the SELECT trial publication and the FDA approval letter to your appeal if the initial PA is denied.
4. If your commercial plan denies twice, request an external independent review, which is a right under the ACA for non-grandfathered plans.
5. If you are uninsured or underinsured, contact Novo Nordisk's Patient Assistance Program directly. Income-based free or reduced-cost drug programs exist and do not require insurance.